To hear about similar clinical trials, please enter your email below
Trial Title:
SHR-A1921 Combined With Adebrelimab in the Treatment of Advanced NSCLC Who Failed the Previous Standard First-line Treatment
NCT ID:
NCT06480136
Condition:
NSCLC
Conditions: Official terms:
Carcinoma, Non-Small-Cell Lung
Conditions: Keywords:
Trop-2 ADC
Study type:
Interventional
Study phase:
Phase 2
Overall status:
Not yet recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
SHR-A1921 injection and adebrelimab injection
Description:
The Treatment group receive SHR-A1921 injection combined with adebrelimab injection
Arm group label:
Treatment group
Summary:
This is a Phase II clinical study to evaluate the efficacy and safety of SHR-A1921
conbined with adebrelimab in advanced NSCLC who failed the previous first-line standard
therapy. Subjects in this study were treated with SHR-A1921 in combination with
adebrelimab until disease progression, intolerable toxicity occurs, informed consent is
withdrawn, or other conditions requiring termination of medication, whichever occurred
first. The maximum treatment time of adebrelimab is 35 cycles or 2 years (whichever comes
first), and subjects can continue to be treated with SHR-A1921 until disease progression,
intolerable toxicity occurs, informed consent is withdrawn, or other conditions requiring
termination of medication. Primary objective of this study was to evaluate the efficacy
of SHR-A1921 combined with adebrelimab in advanced NSCLC who failed the previous
first-line standard therapy. Secondary objective of this study was to evaluate the safety
of SHR-A1921 combined with adebrelimab in advanced NSCLC who failed the previous
first-line standard therapy; Exploratory objective of this study was to evaluate the
biomarker changes during treatment with SHR-A1921 combined with adebrelimab in patients
with advanced NSCLC who failed the previous first-line standard therapy.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
1. Willing to join in this study, signed informed consent, good adherence, can
cooperate with the follow-up;
2. Age 18-75 years old, both genders;
3. Patients with histologically or cytologically confirmed advanced or metastatic
NSCLC（Advanced stage is defined as stage IIIb-IV according to the 8th edition of the
IASLC TNM staging criteria), and no longer suitable for radical surgery or
radiotherapy combined with chemotherapy；
4. Participants with nonsquamous tumors were required to have available genetic testing
to confirm without EGFR, ALK, or ROS1 driver mutations;
5. Disease progression after prior immunization (PD-1/L1 antibody)or combined with
platinum-based chemotherapy;
6. At least one measurable lesion that met RECIST v1.1 criteria;
7. ECOG Performance Status of 0-1;
8. Must have life-expectancy of ≥ 12 weeks;
9. Adequate function of marrow and major organs meets the following requirements：
1. Blood routine (no blood transfusion or granulocyte colony-stimulating factor
therapy within 14 days before examination)：ANC≥1.5×109/L；PLT≥75×109/L；Hb≥90
g/L;
2. Liver function (no hepatoprotective drugs within 7 days before the
examination): ALT and AST≤3 × ULN (liver metastasis≤5.0 × ULN); TBIL≤1.5 ×
ULN（Gilbert's syndrome subjects: TBIL≤3mg/dL）;
3. Renal function:Cr≤1.5 × ULN or creatinine clearance ≥60 mL / min
(Cockcroft-Gault formula)；
4. Coagulation: INR or PT≤1.5×ULN，APTT≤1.5×ULN；
5. Cardiac ultrasound: LVEF≥50%;
10. Female patients of childbearing age or male patients whose partner was a female of
childbearing age had to consent to use a highly effective method of contraception
for the duration of the study and for 6 months after the last dose of study drug;
and have no plans to have children or to donate sperm or eggs, Childbearing age
female patients who were not surgically sterilized had to undergo a serum pregnancy
test with a negative result within 7 days before starting study treatment.；
Exclusion Criteria:
1. Previous receipt of any drug containing a topoisomerase I inhibitor drug, including
antibody-drug conjugates;
2. Previous receipt of TROP2-targeted therapy;
3. Grade 3 or above immune-related adverse events occurred during previous
immunotherapy, such as immune-related interstitial lung disease, immune-related
myocarditis, immune hepatitis, etc.
4. More than 10% of the tumor tissue was histologically or cytologically confirmed as
small-cell lung cancer, neuroendocrine carcinoma, carcinosarcoma;
5. Untreated brain metastasis, or associated with meningeal metastasis, spinal cord
compression, etc. Patients who had received previous treatment for brain metastases
(radiotherapy or surgery) were eligible for enrollment if they had been stable for
at least 4 weeks as confirmed by imaging and had been free of systemic hormone
therapy (at a dose of >10 mg per day of prednisone or the equivalent) for more than
2 weeks and were asymptomatic;
6. Spinal cord compression that could not be cured by surgery and/or radiotherapy;
7. Patients with uncontrolled cancer-related pain as judged by the investigator;
8. Patients with symptomatic pleural effusion, pericardial effusion, or ascites
requiring drainage or those who had undergone therapeutic drainage of serous
effusion within 2 weeks before the administration of the study drug;
9. Patients who received anti-tumor therapy such as chemotherapy within 4 weeks before
the first dose of medication, or received lung field radiotherapy >30Gy within 6
months before the first dose of medication;
10. Major organ surgery or major trauma within 4 weeks before the first dose of the
study drug;
11. Other malignant tumors occurred within 5 years before the first treatment;
12. Patients with a history of interstitial lung disease such as idiopathic pulmonary
fibrosis or imaging examination at screening that suspected interstitial pneumonia
or could not rule out interstitial pneumonia;
13. Active pulmonary tuberculosis infection was detected by medical history or CT
examination within 1 year before enrolment;
14. Severe infection within 4 weeks before the first dose of medication;
15. Have serious cardiovascular and cerebrovascular diseases;
16. Patients with clinically significant bleeding symptoms within 3 months before the
first study medication;
17. Arterial/venous thrombotic events within 6 months before the first dose of study
medication;
18. Hypertension that is not well controlled with antihypertensive medication (systolic
blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg); A history of
hypertensive crisis or hypertensive encephalopathy;
19. Refractory nausea, vomiting, chronic gastrointestinal diseases, etc.
20. Subjects with active, known or suspected autoimmune disease (including
Hiv-Positive), or a history of organ transplantation;
21. Presence of active hepatitis B or C;
22. A live or attenuated vaccine was administered within 4 weeks before the first dose
of the study drug;
23. The adverse reactions of antineoplastic therapy have not recovered to NCI-CTCAE v5.0
grade ≤ 1;
24. A history of severe allergic reaction with other monoclonal antibodies or have
allergic reactions to any component of SHR-A1921 and adbelimumab;
25. According to the investigator's judgment, there are other factors that may affect
the results of the study or lead to the forced termination of the study, such as
alcohol abuse, drug abuse, other serious diseases (including mental diseases)
requiring combined treatment, serious laboratory test abnormalities, accompanied by
family or social factors, which will affect the safety of the subjects.
Gender:
All
Minimum age:
18 Years
Maximum age:
75 Years
Healthy volunteers:
No
Start date:
July 15, 2024
Completion date:
February 15, 2028
Lead sponsor:
Agency:
Shanghai Pulmonary Hospital, Shanghai, China
Agency class:
Other
Source:
Shanghai Pulmonary Hospital, Shanghai, China
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06480136
